Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | Q9HBH1 | 1/20 | 0.40 | |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601223 | 0.91 | PDF (0.42) | KMT2AMEN1BMP1PDFTSHR | |
| SCHEMBL4884598 | 0.91 | PDF (0.42) | KMT2AMEN1BMP1PDFTSHR | |
| SCHEMBL4602747 | 0.91 | PDF (0.41) | ALDH1A1MMP2MMP3BMP1PDF | |
| SCHEMBL4604487 | 0.91 | KMT2A (0.41) | KMT2AMEN1MMP2MMP3PDF | |
| SCHEMBL4602320 | 0.90 | NPSR1 (0.46) | KMT2AMEN1MMP2MMP3BMP1 | |
| SCHEMBL13333263 | 0.90 | LMNA (0.45) | KMT2AMEN1ALDH1A1MMP2MMP3 | |
| SCHEMBL4884508 | 0.89 | KMT2A (0.44) | KMT2AMEN1ALDH1A1DPP4DPP8 | |
| SCHEMBL4601109 | 0.89 | KMT2A (0.44) | KMT2AMEN1ALDH1A1DPP4DPP8 | |
| SCHEMBL14075631 | 0.88 | KMT2A (0.42) | KMT2AMEN1ALDH1A1DPP4DPP8 | |
| SCHEMBL4885175 | 0.85 | MMP3 (0.56) | MMP2MMP3PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| EP-1915342-A1 | A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006115353-A9 | A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006115353-A1 | A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | KMT2A 1445/4885MEN1 3235/4885ALDH1A1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.